• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单剂量 1cp-LSD 给药治疗犬焦虑症:一项初步研究。

Single-dose 1cp-LSD administration for canine anxiety: a pilot study.

机构信息

Unit of Toxicology, Clinical Sciences Department, Universidad de Las Palmas de Gran Canaria, Paseo Blas Cabrera Felipe, s/n., Las Palmas de Gran Canaria, Canary Islands, CP 35016, Spain.

Asociación Científica Psicodélica, Las Palmas de Gran Canaria, Canary Islands, Spain.

出版信息

Vet Res Commun. 2024 Dec;48(6):4007-4014. doi: 10.1007/s11259-024-10542-6. Epub 2024 Sep 17.

DOI:10.1007/s11259-024-10542-6
PMID:39287896
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11538183/
Abstract

Anxiety affects 14-20% of dogs. Pharmacological treatments often fail. Psychedelics have shown to be useful for anxiety and depression in humans, but their veterinary use remains unexplored. We aimed to determine the effects of low-dose 1-cyclopropionyl-d-lysergic acid diethylamide (1cp-LSD) administered in a single dose to a dog, to observe the effect and establish the safety of the substance. The patient was a 13-year-old female dog, weighing 13 kg, mixed breed, and spayed. A total of 5 µg was administered orally, equivalent to 0.38 µg/kg. The animal has had a history of separation related behavioral problems throughout her life. To objectively assess the degree of anxiety in the dog, a validated scale was utilized. The trial was scheduled at the house where the animal lives. The owner was present throughout the experience. Informed consent was obtained prior to the assay. The trial began at 12:15 p.m. on January 10, 2024, lasting for 5 and a half hours. The response to anxiety-inducing stimuli was equally anxious during the first two hours. From that point onwards, a significant change in the animal's behavior was observed, with no signs/mild signs of anxiety. The trial concluded without any adverse effects on the animal. The patient did not show signs of having a psychedelic experience. This is the first time that a study of this nature has been conducted and reported in the canine species. 1cp-LSD proved to be safe and exerted the desired effect on the animal's behavior, significantly reducing the patient's anxiety.

摘要

焦虑影响 14-20%的狗。药物治疗往往失败。迷幻剂已被证明对人类的焦虑和抑郁有效,但它们在兽医中的应用仍未得到探索。我们的目的是确定单剂量给予狗低剂量 1-环丙基-D-麦角酸二乙酰胺(1cp-LSD)的效果,观察该物质的效果并确定其安全性。患者是一只 13 岁的雌性狗,体重 13 公斤,混合品种,已绝育。总共给予 5µg,相当于 0.38µg/kg。该动物一生都有与分离相关的行为问题史。为了客观评估狗的焦虑程度,使用了经过验证的量表。试验安排在动物居住的家中进行。主人全程在场。在进行测定之前获得了知情同意。试验于 2024 年 1 月 10 日下午 12 点 15 分开始,持续了 5 个半小时。在头两个小时内,对引起焦虑的刺激的反应同样焦虑。从那时起,观察到动物行为发生了显著变化,没有焦虑迹象/轻度焦虑迹象。试验在没有对动物造成任何不良影响的情况下结束。患者没有表现出具有迷幻体验的迹象。这是首次在犬科动物中进行此类研究并报告。1cp-LSD 被证明是安全的,并对动物的行为产生了预期的效果,显著减轻了患者的焦虑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9297/11538183/65fee9097412/11259_2024_10542_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9297/11538183/dd4c2ed16c6e/11259_2024_10542_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9297/11538183/65fee9097412/11259_2024_10542_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9297/11538183/dd4c2ed16c6e/11259_2024_10542_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9297/11538183/65fee9097412/11259_2024_10542_Fig2_HTML.jpg

相似文献

1
Single-dose 1cp-LSD administration for canine anxiety: a pilot study.单剂量 1cp-LSD 给药治疗犬焦虑症:一项初步研究。
Vet Res Commun. 2024 Dec;48(6):4007-4014. doi: 10.1007/s11259-024-10542-6. Epub 2024 Sep 17.
2
Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD).麦角酰二乙胺的卷土重来。第六部分:1-环丙甲酰基-D-麦角酸二乙酰胺(1CP-LSD)的分析和行为特征。
Drug Test Anal. 2020 Jun;12(6):812-826. doi: 10.1002/dta.2789. Epub 2020 Apr 20.
3
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.致幻剂辅助治疗对患有危及生命疾病的人群的焦虑、抑郁和存在性困扰的治疗作用。
Cochrane Database Syst Rev. 2024 Sep 12;9(9):CD015383. doi: 10.1002/14651858.CD015383.pub2.
4
Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).麦角酰二乙酰胺的重现。第五部分:1-丁酰基-D-麦角酸二乙基酰胺(1B-LSD)的分析和行为特征。
Drug Test Anal. 2019 Aug;11(8):1122-1133. doi: 10.1002/dta.2613. Epub 2019 Jun 18.
5
Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).麦角酰胺类药物的回归。第一部分:1-丙酰基-d-麦角酸二乙酰胺(1P-LSD)的分析与行为特征
Drug Test Anal. 2016 Sep;8(9):891-902. doi: 10.1002/dta.1884. Epub 2015 Oct 12.
6
Long-lasting subjective effects of LSD in normal subjects.正常受试者中 LSD 的持久主观效应。
Psychopharmacology (Berl). 2018 Feb;235(2):535-545. doi: 10.1007/s00213-017-4733-3. Epub 2017 Sep 16.
7
LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up.LSD 辅助治疗焦虑症患者:开放标签前瞻性 12 个月随访。
Br J Psychiatry. 2024 Sep;225(3):362-370. doi: 10.1192/bjp.2024.99.
8
Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline.反复给予麦角酸二乙基酰胺(LSD)可逆转应激引起的焦虑样行为、皮质突触发生缺陷和血清素能神经传递下降。
Neuropsychopharmacology. 2022 May;47(6):1188-1198. doi: 10.1038/s41386-022-01301-9. Epub 2022 Mar 17.
9
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers.低剂量麦角酸二乙酰胺可降低健康志愿者的疼痛感知。
J Psychopharmacol. 2021 Apr;35(4):398-405. doi: 10.1177/0269881120940937. Epub 2020 Aug 25.
10
Phospholipase C mediates (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex.磷酸脂酶 C 介导(±)-1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷(DOI),而不是麦角酸二乙基酰胺(LSD)引发的兔内侧前额叶皮层的头部摆动。
Brain Res. 2013 Jan 23;1491:98-108. doi: 10.1016/j.brainres.2012.10.057. Epub 2012 Nov 1.

引用本文的文献

1
Evaluating the Potential of Microdosing 1cp-LSD for the Treatment of Canine Anxiety: A One-Month Case Study.评估微剂量1-环己基哌啶-LSD治疗犬类焦虑症的潜力:一项为期一个月的案例研究。
Vet Med Sci. 2025 Jul;11(4):e70486. doi: 10.1002/vms3.70486.

本文引用的文献

1
Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study.设置和情境预测致幻体验的精神病理学、幸福感和意义:一项相关性研究。
Expert Rev Clin Pharmacol. 2024 Jan-Jun;17(2):165-176. doi: 10.1080/17512433.2023.2295997. Epub 2024 Jan 29.
2
Veterinary Psychopharmacology.兽医精神药理学
Vet Clin North Am Small Anim Pract. 2024 Jan;54(1):195-205. doi: 10.1016/j.cvsm.2023.07.003. Epub 2023 Aug 28.
3
Combining α-s1 Casozepine and Fluoxetine Treatment with a Behavioral Therapy Improves Symptoms in an Aggressive Dog: An Italian Case Report.
将α-s1酪蛋白和氟西汀治疗与行为疗法相结合可改善一只攻击性犬的症状:一份意大利病例报告。
Vet Sci. 2023 Jul 4;10(7):435. doi: 10.3390/vetsci10070435.
4
Assessment of cannabidiol use in pets according to a national survey in the USA.根据美国的一项全国性调查评估宠物使用大麻二酚的情况。
J Small Anim Pract. 2023 Aug;64(8):513-521. doi: 10.1111/jsap.13619. Epub 2023 May 19.
5
Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.健康志愿者中小剂量麦角酸二乙酰胺的急性情绪提升作用:一项家庭管理的随机对照试验。
Biol Psychiatry. 2023 Sep 15;94(6):511-521. doi: 10.1016/j.biopsych.2023.03.013. Epub 2023 Mar 28.
6
Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines.霍夫曼与帕拉塞尔苏斯:致幻剂是否违背毒理学基本原理?——对主要麦角胺、简单色胺和苯乙胺的系统评价
Toxics. 2023 Feb 3;11(2):148. doi: 10.3390/toxics11020148.
7
Intoxication of dogs and cats with common stimulating, hallucinogenic and dissociative recreational drugs.犬猫因常见的刺激性、致幻性和解离性消遣性药物而中毒。
Vet Anim Sci. 2023 Jan 31;19:100288. doi: 10.1016/j.vas.2023.100288. eCollection 2023 Mar.
8
The neural basis of psychedelic action.迷幻剂作用的神经基础。
Nat Neurosci. 2022 Nov;25(11):1407-1419. doi: 10.1038/s41593-022-01177-4. Epub 2022 Oct 24.
9
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.迷幻剂:治疗情绪和焦虑障碍的替代和潜在治疗选择。
Molecules. 2022 Apr 14;27(8):2520. doi: 10.3390/molecules27082520.
10
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.迷幻剂的不良反应:从传闻和错误信息到系统科学。
J Psychopharmacol. 2022 Mar;36(3):258-272. doi: 10.1177/02698811211069100. Epub 2022 Feb 2.